[Amyloidosis].

Amyloidosis are rare protein misfolding and deposition diseases which, with very few exceptions, are treatable easily nowadays. The prognosis depends on the form of amyloidosis, which is particularly unfavorable for heart involvement that is diagnosed too late. Patients die within months to a few years or suffer irreversible loss of function of the affected organs. Once the diagnosis has been made, treatment should be started without delay. Amyloidosis centers offer support in the diagnosis and development as well as clinical trials of an optimal therapy concept.

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Prof. Hegenbart: Honorarium for talks: Janssen, Pfizer, Alnylam, Akcea, Prothena, Astra Zeneca (honorary received by institution) Financial support of congress participation; Janssen, Prothena, Pfizer Advisory Boards: Pfizer, Prothena, Janssen, Alexion, Alnylam Financial sponsoring of Amyloidosis Registry: Janssen, Prothena (received by institution) Prof. Schönland: Consultant/Adviserfor and received travel grant, honoraria, and research funding from Janssen and Prothena; received research funding from Sanofi; received honoraria from Pfizer and Takeda; and is an adviser for Telix; received travel grants from Binding Site, Celgene, and Jazz.